Work

Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors

Year: 2007

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdm140

Authors: S Hariharan, D Gustafson, S Holden, D McConkey, D Davis, M Morrow, M Basche, L Gore, C Zang, C.L. O'Bryant, A Baron, D Gallemann, D Colevas, S.G. Eckhardt

Institutions: University of Colorado Cancer Center, The University of Texas MD Anderson Cancer Center, Merck KGaA, Darmstadt (Germany), National Institutes of Health, National Cancer Institute

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Abbott Laboratories, National Cancer Institute

Awards: Development of Mechanism-Based Anticancer Therapy, Phase I Trials of Anticancer Agents

OpenAlex ID: W2072700424

FWCI: 3.838

Cites: 43

Cited by: 128

Related to: 10